The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Great update. Thanks
it's been a rough week for the nasdaq biotech index and the uk plays on it like IBT and BIOG. IVO is undeniably heavily exposed to life science. perhaps that has something to do with it. IVO is so illiquid that it can trade in odd ways in the shorter term anyway, so i wouldn't read too much into it. Note, Numis also gave peer/competitor IP Group a push today, raising price target.
Really strange that a Director buys nearly £70,000 of shares at the market oprice and the share price drops. Any ideas?
In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive.[citation needed] The assignment of orphan status to a disease and to any drugs developed to treat it, is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.[1]
The investment case for Imperial Innovations rests in the potential to unlock hidden value from within its portfolio of 95 companies, which span healthcare (therapeutic/medtech), engineering/materials and ICT/digital. Healthcare currently accounts for c 70% of the portfolio value (£252m at 31 July 2014), although Innovations’ management plans a rebalance to c 60% healthcare and c 40% technology (engineering/materials and ICT/digital). In this special report we highlight the potential within the technology portfolio, profiling seven companies that could add substantial value over the next few years, above their relatively modest carrying values.
Edison Research on IVO http://www.edisoninvestmentresearch.com/research/report/imperial-innovations21
Nice 3.93% rise in the share price. Has anyone got any ideas why?
in the RNS - but how good? Noticed the guy at Penny Sleuth David Thornton tipping them 2 days ago. GL Holders.
a regular stream of small buyers being attracted to this company. Shares very tightly held with perhaps less than 10% outside the hands of 4 big shareholders and the directors so when this starts to move it will move quickly. Need to narrow the spread to attract more interest. Rgds
Russ Cummings, the chief executive of Imperial Innovations (LON:IVO), says the university commercialisation business is in a strong position after its recent fundraising. He says the £150mln placing will last the company ‘a good, long period’ and adds that so-called tax inversion deals ‘don’t really affect us’. The group’s annual results today showed a 38% rise in the value of its portfolio to £252mln. http://tinyurl.com/krmarxg
Imperial Innovations Group has proposed raising up to £150m through the placement of shares to fund its existing portfolio and source investment opportunities in new technologies. The UK technology transfer and commercialisation company will place ordinary shares at no less than 400p each. Chairman Martin Knight, said: "The board believes that strengthening the group's balance sheet through the placing would greatly enhance its ability to attract high quality investment opportunities. "It would also improve the group's ability to support portfolio companies from inception until their full development, as illustrated by the recent successful initial public offering of Circassia Pharmaceuticals."
12 September 2013 Imperial Innovations Group plc Circassia's house dust mite allergy treatment achieves long-term symptom reduction Imperial Innovations Group plc (AIM: IVO, "Innovations"), the leading technology commercialisation and investment group, announces that portfolio company Circassia, the specialty biopharmaceutical company focused on allergy, has achieved successful results from a phase II clinical study of its house dust mite allergy treatment. Patients who received four doses of the treatment over 12 weeks had significantly improved allergy symptoms one year after the start of the trial compared with placebo, meeting the study's long-term primary endpoint. The trial was conducted in Toronto, Canada, where 172 volunteers with confirmed house dust mite allergy received one of four treatment regimens or placebo. Investigators measured patients' allergy symptoms when exposed to house dust mite allergens, at the start and during the 12-month study. Circassia has submitted the study results for presentation at a leading scientific conference. House dust mites are found widely throughout homes, in bedding, carpets, soft furnishings and clothing. Allergy to proteins in the mites' droppings is extremely common, and often associated with asthma. In the United States and Europe, approximately one in four people are sensitised to house dust mites, with more people having allergic responses than to any other common allergen. House dust mite allergy is a perennial condition that can impact sufferers' education, work, quality of life and social activities. Other allergies for which Circassia is developing a treatment include cat, currently in phase III trials and grass, currently in phase II. Russ Cummings, CEO of Innovations, said: "The long term success of Circassia's house dust mite allergy treatment endorses the potential of its allergy treatment platform. This progress is a great demonstration of the value that is being developed within Innovations' portfolio of technologies." Steve Harris, CEO of Circassia added: "These results reflect the significant long-term improvements we achieved with a similar short-course of our cat allergy treatment, reinforcing the effectiveness of our platform for allergy treatments. "In many countries, house dust mites are responsible for more allergies than any other allergen, causing year-round suffering for millions of people. This trial demonstrates the potential of our ToleroMune(R) technology to reduce sufferers' symptoms long term, and to revolutionise allergy therapy by achieving this with a simple short course of treatment."
After more than ten years, where are the exits?
Susan Searle, Chief Executive Officer of Innovations, said: "Backing from such a strong global company as WACKER is a great endorsement of Nexeon's silicon anode battery technology. The strategic partnership will enable Nexeon to accelerate the production and commercialisation of its materials. Nexeon's success demonstrates that our strategy to accelerate and increase investment in selected technologies is resulting in some really strong portfolio companies." Dr Scott Brown, Chief Executive Officer of Nexeon said: "WACKER has an enviable track record of bringing innovative products to demanding global markets, and its large scale silicon processing expertise will allow us to accelerate our scale-up plans significantly."
AIM-listed technology commercialisation and investment group Imperial Innovations has announced that portfolio company Nexeon, a battery materials and licensing company, has signed a strategic partnership agreement with German chemical company WACKER Chemie AG (WACKER). The group reported that WACKER has taken a strategic stake in Nexeon. The partnership will involve the two companies working together to scale-up the production of Nexeon's silicon anode technology to commercial volumes. WACKER has research and chemical process capabilities as well as extensive production expertise in speciality materials and will be able to leverage its engineering and manufacturing expertise to accelerate Nexeon's scale-up plans. Nexeon, which is Innovations' second largest investment to date, is developing silicon materials to replace carbon as the anode of lithium ion batteries.
Technology commercialisation and investment group Imperial Innovations has invested 1.5m pounds in technology firm Semetric, the company behind global music analytics specialist, Musicmetric. The group said that the investment was part of a £3m funding round which also included its existing investor Pentech Ventures LLP. Commenting on the development, Susan Searle, Chief Executive Officer of Imperial Innovations, said: "Semetric's platform offers customers tangible insight into consumer behaviour, enabling brands and music companies to make better marketing and promotion decisions. With a strong and experienced team in place, Semetric is poised to make an impact across a range of media verticals. We are delighted to be making this investment, our second alongside Pentech Ventures." Greg Mead, Chief Executive Officer of Semetric, said: "The Musicmetric brand has become synonymous with music analytics and this investment will further enable us to develop the Semetric technology platform and drive similar success across television and film analytics. We are pleased that Imperial Innovations have recognised the huge opportunities that exist in media analytics, and welcome their support at this exciting time for the business."
Valuation: Look for growth in portfolio value We contend the basis for investment in Imperial Innovations is the expectation of future portfolio value appreciation and realisations. This should arise from successful IP commercialisation by portfolio companies and be crystallised by liquidity events. Imperial Innovations has historically been able to grow the value of its portfolio over and above the net new investment and has also traded at a premium to NAV, which can be ascribed in part to hidden (unrealised) value in portfolio companies.
http://www.edisoninvestmentresearch.co.uk/researchreports/IVO_Update_101012.pdf
Valuation: Look for growth in the portfolio value We contend the basis for investment in Imperial Innovations is the expectation of future portfolio value appreciation and realisations. This should arise from successful IP commercialisation by portfolio companies and be crystallised by liquidity events. Imperial Innovations has historically been able to grow the value of its portfolio over and above the net new investment and has also traded at a premium to NAV, which can be ascribed in part to hidden (unrealised) value in portfolio companies.
Valuation: It’s all in the portfolio We contend the basis for investment in Imperial Innovations is the expectation of future portfolio value appreciation and realisations. This should arise from successful IP commercialisation by portfolio companies and be crystallised by liquidity events. The company’s portfolio has now matured to the point where this investment opportunity can be better understood
Susan Searle, Chief Executive Officer, Imperial Innovations, said: "PsiOxus continues to make great strides in translating its novel science into therapies that address major unmet medical needs for patients. We believe that ColoAd1 can represent a significant breakthrough in oncolytic vaccines and has the potential to open an entirely new approach to cancer therapy." Dr John Beadle, Chief Executive Officer, PsiOxus, said: "This financing comes at a pivotal time for our company as we move our cancer portfolio from early- to mid-stage clinical development. The new funding will enable key clinical trials to demonstrate the safety and proof of efficacy of these products in the clinic and to highlight the effectiveness of our research and development program. We are delighted to have the continued support of our existing investors and proud to add the support of SR ONE and the Lundbeck Fund giving us a truly exceptional group of investors."
Innovations leads £22m funding round for PsiOxus Therapeutics Imperial Innovations Group plc (AIM: IVO, 'Innovations'), a leading technology commercialisation and investment group, has led a £22m funding round for PsiOxus Therapeutics, alongside Invesco Perpetual, and together with new investors SR One and Lundbeckfond Ventures. PsiOxus Therapeutics, based in Oxfordshire, is a development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer, wasting diseases and other unmet clinical needs. PsiOxus will use the funds to advance the clinical development of ColoAd1, a highly potent broad-spectrum anti-cancer therapeutic capable of destroying tumour cells at minute concentrations. A series of phase I and phase II clinical trials for the treatment of colorectal cancer and other forms of solid cancer will be initiated. ColoAd1 is a unique therapeutic candidate developed using the evolutionary principle of natural selection to generate an oncolytic vaccine with optimal anti-cancer properties. The first clinical trial of ColoAd1 will be initiated later this year in patients with metastatic solid tumours, to determine the safety and tolerability of the vaccine. Innovations and Invesco Perpetual each invested £5.5 million in this round. The company was also supported by new investors SR One and Lundbeckfond Ventures who invested the remaining £11 million. Following the investment Innovations will hold a 26% stake in the Company.
http://www.investegate.co.uk/Article.aspx?id=201207090700091642H